HAURAKI PHO
  • Home
  • About us
    • Our People
  • Services We Offer
    • HPHO Practices
    • After Hours Services
    • Breast and Cervical Screening Support
    • Diabetes Management
    • Heart Check
    • Ngā Kaitiaki Manawanui Whai Ora
    • Outreach Immunisation Service
    • Primary Options
    • Patient Portal
    • Primary Mental Health Services
    • Shared Electronic Health Record
  • News & Support
    • Education and Training
    • Coronavirus Updates >
      • COVID-19 Vaccine Updates
    • Join the Team!
  • Contact
  • Home
  • About us
    • Our People
  • Services We Offer
    • HPHO Practices
    • After Hours Services
    • Breast and Cervical Screening Support
    • Diabetes Management
    • Heart Check
    • Ngā Kaitiaki Manawanui Whai Ora
    • Outreach Immunisation Service
    • Primary Options
    • Patient Portal
    • Primary Mental Health Services
    • Shared Electronic Health Record
  • News & Support
    • Education and Training
    • Coronavirus Updates >
      • COVID-19 Vaccine Updates
    • Join the Team!
  • Contact

Pharmac consultation on adalimumab biosimilar

26/8/2021

 
Kia ora,
 
Pharmac is consulting on a proposal to widen access to, and award principal supply of adalimumab (biosimilar).
 
We want to hear from people about this proposal which would give more New Zealanders access to adalimumab.
 
Please share this information
 
We want to make sure everyone who might be interested is aware of these proposed changes. Please share this information with people you think might want to provide feedback on this consultation.
 
continued...
Details about this proposal
 
We are proposing to make changes to the funded brand of adalimumab, from Humira to a citrate-free biosimilar called Amgevita. Amgevita is Medsafe registered and is supplied by Amgen in more than 40 countries around the world.
 
If the proposal is approved, a number of changes would occur. These include:
  • Access to adalimumab (Amgevita) treatment would be widened for a range of uses, both new uses and to enable improved access to adalimumab treatment for currently funded uses.  
  • A biosimilar adalimumab (Amgevita) would be funded from 1 February for all people starting on adalimumab treatment.
  • People receiving treatment with the currently funded brand of adalimumab (Humira) before 1 February 2022 would move to Amgevita before 31 August 2022.
  • Humira would remain funded for people who cannot successfully transition to Amgevita. This would mean these patients can continue receiving (or go back to receiving) funded treatment with Humira, in consultation with their prescriber.
More information on the changes that would occur if this proposal were to be approved is available in the attached consultation document.
 
Submitting your feedback
 
We welcome and value your feedback on this proposal. Please provide feedback by 5 pm, Wednesday 22 September 2021. Feedback can be submitted using this webform or emailed to consult@pharmac.govt.nz.


Comments are closed.

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    March 2022
    February 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020

    Categories

    All

    RSS Feed

THAMES
106 Sealey Street, Thames 3500
phone 07-868-9686
Send us a message
HAMILTON
​16 Von Tempsky Street, Hamilton East
​Hamilton 3216

phone 07-868-9686
Send us a message
Picture
Copyright © Hauraki Primary Health Organisation  |  2020